Navigation Links
Genzyme Launches Cholestagel(R) in Europe
Date:10/23/2007

rolemia (FH) -- an inherited disorder that causes exceptionally high levels of LDL-cholesterol -- who cannot reach their target LDL- cholesterol levels with a maximum regimen of statins and ezetimibe alone.

This double-blind, randomized "TRIPLE" study will involve 80 patients with FH enrolled in six European centers (including in the UK, Netherlands, Sweden and France) and preliminary results are expected in Q3 2008.

"Patients with genetic conditions like familial hypercholesterolemia are at particularly high risk of early coronary heart disease," said Dr. Anthony Wierzbicki, from London's St. Thomas' Hospital and a board member and chairman of the Medical Scientific and Research Committee of FH patient association 'Heart UK'. "Patients have to take multiple cholesterol-lowering therapies and yet still often require further cholesterol reduction to reach target lipid levels recommended for patients at risk of cardiovascular events. New non-systemic agents are a welcome addition for these patients to help them achieve these targets."

Unlike most other cholesterol-lowering treatments, Cholestagel is non- systemic, and therefore is not absorbed into the bloodstream. Cholestagel binds bile acids in the intestine, impeding their reabsorption. This process -- called bile acid sequestration -- results in an increased clearance of LDL cholesterol from the blood. Cholestagel is also well tolerated, with minimal gastrointestinal side effects similar to those seen in placebo, and has limited drug-interaction.

Colesevelam has been approved for use in the United States since 2000, where it is marketed by Daiichi Sankyo Inc. under the trade name WelChol(R). Genzyme plans to launch Cholestagel in the United Kingdom, the Netherlands and the Scandinavian region this quarter, and in additional European countries next year. Genzyme also intends to pursue regulatory approvals for Cholestagel in Latin America, Canada, and the Asia Pacific region.

Genzyme ha
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Cytochroma settles lawsuit with Genzyme
2. Genzyme sues former Bone Care employees
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. Merge launches diagnostic mammography workstation in Europe
5. Einstein Wireless launches cellular alert system
6. Logistics Health launches compliance management tool
7. UW-Madison launches new high-speed research network
8. UWM launches research foundation
9. TeraMedica launches information manager
10. GE Healthcare launches hybrid electronic record
11. Cedara launches new version of DICOM toolkit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 Can economic incentives such ... motivate members of the public to increase their donations ... Johns Hopkins Carey Business School Assistant Professor Mario ... to a large body of recent research that supports ... 24, 2013, issue of Science that the World Health ...
(Date:5/23/2013)... SCHOFIELD, Wis. , May 23, 2013 /PRNewswire/ ... a researcher, developer, and marketer of over-the-counter (OTC) ... re-issued its research opinion on the company based ... Highlights , Non-Prescription, All Natural Product ... Show the Product Outperforms #1 Prescription Competitor ...
(Date:5/23/2013)... PI’s new LPS-24 positioners are ... mm travel range with closed-loop sensor resolution up ... these new positioners the ideal choice for high ... version is also available. , More Information: ... be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 , ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
... Interleukin Genetics, Inc. (OTCQB: ILIU) announced today ... Thursday, November 10 at 4:30 p.m. (EST) to discuss the ... call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live Webcast ... the Investors section of Interleukin Genetics, Inc.,s Website at ...
... Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ), ... gastroenterology markets, today announced third quarter 2011 financial results. ... September 30, 2011, net revenue was $13.1 million, up from ... net revenue was driven by an increase in sales of ...
... NEW YORK, Nov. 3, 2011 Reportlinker.com announces ... in its catalogue: Global ... http://www.reportlinker.com/p0619270/Global-Biochip-Markets-Microarrays-and-Lab-on-a-Chip.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory INTRODUCTION  ... BCC,s goal for this study ...
Cached Biology Technology:Interleukin Genetics, Inc. Announces Conference Call to Discuss Third Quarter 2011 Results 2Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 2Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 3Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 4Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 5Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 6Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 7Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 8Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 9Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 10Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 11Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 12Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Global Biochip Markets: Microarrays and Lab-on-a-Chip 5
(Date:5/23/2013)... microbial pathogens are growing increasingly resistant to the conventional ... Wisconsin scientists has synthesized a potent new class of ... infections. , Writing online in the Journal of ... University of Wisconsin-Madison chemistry Professor Helen Blackwell describes agents ... Staphylococcus aureus , a bacterium at the root ...
(Date:5/22/2013)... improve durability in fuel cell powered buses, including ... links between electrode degradation processes and bus membrane ... of electrode degradation stressors in the operating cycle ... The findings of the study, led by SFU ... a long-term study at Burnaby-based Ballard Power Systems ...
(Date:5/22/2013)... Md. (May 22, 2013)The omega 3 fatty acids in ... cardiovascular diseaseso much so that the American Heart Association ... a week, particularly fatty varieties rich in omega 3s. ... a mystery. In a new study, scientists led by ... on this phenomenon by providing evidence that fish oil ...
Breaking Biology News(10 mins):University of Wisconsin chemists find new compounds to curb staph infection 2Tests lead to doubling of fuel cell life 2Fish oil may help the heart beat mental stress 2
... 2009 News reports last week about scuba divers off ... jumbo squid have raised the ire of University of Rhode ... the species who has dived with them several times, he ... is seriously overblown. For years Seibel has heard stories ...
... In a study released online on July 22 in ... Sciences , researchers at Arizona State University and Princeton ... rationally than our multimodal, egg-headed, tool-using, bipedal, opposing-thumbed ... humans being "stupider" than ants. Humans and animals simply ...
... Researchers at the University of Texas Medical Branch at ... while using depot medroxyprogesterone acetate, more commonly known as Depo-Provera ... that all women who use DMPA will gain weight and ... whose weight increased by 5 percent within the first six ...
Cached Biology News:URI researcher sheds light on 'man-eating' squid; finds them timid, nonthreatening 2URI researcher sheds light on 'man-eating' squid; finds them timid, nonthreatening 3Ants more rational than humans 2UTMB study identifies women at risk of gaining excessive weight with injectable birth control 2
... Gene Knockout System provides optimized reagents and ... of bacterial genes by insertion of group ... ability of group II introns and utilizes ... TargeTron group II intron for specific insertion ...
...
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Mouse polyclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = 25797...
Biology Products: